Citadel Securities Maintains a 'Neutral' on Savient Pharmaceuticals (SVNT); Ilaris FDA Panel Rejection Removes Potential Krystexxa Adoption Overhang
Go back to Citadel Securities Maintains a 'Neutral' on Savient Pharmaceuticals (SVNT); Ilaris FDA Panel Rejection Removes Potential Krystexxa Adoption Overhang| Savient Pharmaceuticals, Inc. (AMEX: SVNT) | Delayed: 40.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $40.05 | 52 Week High | $24.50 | |||
| Open | $24.98 | 52 Week Low | $14.75 | |||
| Day High | $40.05 | P/E | N/A | |||
| Day Low | $40.05 | EPS | $-1.64 | |||
| Volume | 44,442 | |||||
